Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: enzalutamide

Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC

Presented By
Prof. Karim Fizazi, Institute Gustave Roussy, France
Trial
Phase 3, TALAPRO-2
Conference
ASCO 2023

2 August, 2023 09:24

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By
Prof. Gerhardt Attard, UCL Cancer Institute London, UK
Trial
Phase 3, STAMPEDE
Conference
ESMO 2022

17 November, 2022 00:23

Enzalutamide performs well in metastatic hormone-sensitive prostate cancer

Presented By
Prof. Ian Davis, Monash University, Australia
Trial
Phase 3, ENZAMET
Conference
ASCO 2022

5 August, 2022 14:04

Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Presented By
Dr Axel Merseburger, Universitätsklinikum Schleswig-Holstein, Germany
Trial
Phase 3, PRESIDE
Conference
ASCO GU 2022

8 April, 2022 11:24

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial
Phase 3, PEACE-1, STAMPEDE, ARCHES
Conference
ESMO 2021

19 November, 2021 09:27

ARAMIS final OS and nmCRPC safety outcomes

Expert
Prof. Karim Fizazi, Institut Gustave Roussy, France
Trial
Phase 3, ARAMIS
Conference
ASCO 2020

17 September, 2020 14:11

Targeting steroid sulphatase in resistant prostate cancer cells

Presented By
Prof. Allen C. Gao , University of California Davis, USA
Conference
EAU 2020

20 August, 2020 13:00

Enzalutamide offers survival advantage over other NSAAs in mHSPC

Presented By
Dr Christopher Sweeney, Dana-Farber Cancer Institute, USA
Trial
ENZAMET, TITAN
Conference
ASCO 2019

15 July, 2019 23:26

Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer

Presented By
Prof. Antonio Alcaraz, Prof. Noel Clarke
Trial
Phase 3, ARCHES
Conference
EAU 2019

21 May, 2019 23:59
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy